TON - November 2017, Vol 10, No 6

Dr Bruner has had a distinguished career, marked by many awards (most recently, induction into the National Academy of Medicine), the publication of more than 150 peer-reviewed journal articles, and the distinction of being the first and only nurse to lead a National Cancer Institute cooperative group—the Radiation Therapy Oncology Group’s Community Clinical Oncology Program. Read More ›

Immune checkpoint inhibitor therapy is a relatively recent advance in the treatment of several types of cancer and has received much media attention. As healthcare professionals gain more experience with checkpoint inhibitors, it is important for them to understand that the toxicity profiles of these drugs differ from those of chemotherapeutic agents. Read More ›

The National Comprehensive Cancer Network estimates that at least 33% of patients with cancer have significant psychological distress, and many patients have some levels of distress. Read More ›

At the 12th Annual New Orleans Summer Cancer Meeting, Jessica MacIntyre, ARNP, NP-C, AOCNP, Director, Clinical Operations, Office of the Director, and Co-Leader, Oncology Nurse Practitioner Fellowship Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, FL, discussed some of the most impactful supportive care abstracts from the 2017 American Society of Clinical Oncology (ASCO) annual meeting, as well as the potential implications of this new research in the field of nursing. Read More ›

The November issue of The Oncology Nurse-APN/PA (TON) is full of important news and updates for oncology nurses. Read More ›

Patients’ perceptions of worrisome chemotherapy-related side effects have evolved since the 1980s and 1990s, according to a recent survey of women with breast and ovarian cancers that was reported at the 2017 European Society for Medical Oncology Congress. Read More ›

Central obesity increases the risk for developing cancer in postmenopausal women more than high body mass index (BMI) and fat percentage, according to a study reported at the 2017 European Society for Medical Oncology Congress. Read More ›

For patients with metastatic hormone-naïve prostate cancer, practice-changing results from the LATITUDE clinical trial showed that the use of abiraterone plus low-dose prednisone in addition to androgen-deprivation therapy (ADT) delayed disease progression by an average of 18 months, and reduced the risk for death by 38%, when compared with ADT alone. Read More ›

“Our study shows that women who received modern breast radiation therapy overwhelmingly found the treatment experience far better than expected,” said Susan McCloskey, MD, MSHS, at the 2017 American Society for Radiation Oncology annual meeting. Read More ›